Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 sotatercept add-on study in newly diagnosed intermediate- or high-risk pulmonary arterial hypertension
NL-OMON56236Phase 3Recruiting
- Sponsor
- Acceleron Pharma Inc.
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of sotatercept, sponsored by Acceleron Pharma Inc. Started Sep 2022; status: recruiting.
02
Drugs
sotatercept
Beyond the preview
Go deeper on NL-OMON56236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56236.